TW202014437A - 使用抗體之癌症治療 - Google Patents

使用抗體之癌症治療 Download PDF

Info

Publication number
TW202014437A
TW202014437A TW108128652A TW108128652A TW202014437A TW 202014437 A TW202014437 A TW 202014437A TW 108128652 A TW108128652 A TW 108128652A TW 108128652 A TW108128652 A TW 108128652A TW 202014437 A TW202014437 A TW 202014437A
Authority
TW
Taiwan
Prior art keywords
specific binding
cancer
binding molecule
seq
antibody
Prior art date
Application number
TW108128652A
Other languages
English (en)
Chinese (zh)
Inventor
費歐娜 登普賽
克里斯多夫 貝瑞 沃德
蒂娜 Ｃ 法拉圖
史考特 克萊頓
Original Assignee
英商梅德安納克斯有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商梅德安納克斯有限公司 filed Critical 英商梅德安納克斯有限公司
Publication of TW202014437A publication Critical patent/TW202014437A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW108128652A 2018-08-10 2019-08-12 使用抗體之癌症治療 TW202014437A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1813137.5A GB201813137D0 (en) 2018-08-10 2018-08-10 Cancer treatment with an antibody
GB1813137.5 2018-08-10

Publications (1)

Publication Number Publication Date
TW202014437A true TW202014437A (zh) 2020-04-16

Family

ID=63667034

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108128652A TW202014437A (zh) 2018-08-10 2019-08-12 使用抗體之癌症治療

Country Status (12)

Country Link
US (1) US11858982B2 (enExample)
EP (1) EP3833404A1 (enExample)
JP (2) JP7428696B2 (enExample)
KR (1) KR20210088523A (enExample)
CN (1) CN112770786B (enExample)
AU (1) AU2019319092B2 (enExample)
BR (1) BR112021002435A2 (enExample)
GB (1) GB201813137D0 (enExample)
IL (1) IL280421B2 (enExample)
MX (1) MX2021001604A (enExample)
TW (1) TW202014437A (enExample)
WO (1) WO2020030827A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250025553A1 (en) 2021-11-18 2025-01-23 Medannex Ltd. Combination therapy for cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219299A1 (en) 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
US20040219572A1 (en) 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
EP1670510A1 (en) 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
JP5139058B2 (ja) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
CN100571785C (zh) * 2006-09-06 2009-12-23 中国医学科学院北京协和医院 Annexin A3与癌症的铂类化疗药物耐药性的相关性
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
EP2580241B1 (en) * 2010-06-09 2020-11-04 Queen Mary & Westfield College, University of London Annexin 1 antibody
CN102898527B (zh) 2011-07-25 2016-12-21 三星电子株式会社 融合蛋白、药物组合物及预防或治疗癌症的方法
GB201121564D0 (en) 2011-12-14 2012-01-25 Queen Mary & Westfield College Use of antibody
KR20150029457A (ko) 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도
US20160291025A1 (en) 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
CN104277102B (zh) * 2014-06-27 2017-04-12 李光辉 一种检测乳腺癌标志物Annexin A1抗原表位氨基酸序列及应用
GB201702091D0 (en) * 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
US20210292400A1 (en) 2018-05-17 2021-09-23 Yiping W. Han Methods for treating, preventing and detecting the prognosis of colorectal cancer
US20210353721A1 (en) 2018-08-07 2021-11-18 The Brigham And Women's Hospital, Inc. Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1
US20200171165A1 (en) 2018-11-30 2020-06-04 Proteogenomics Research Institute for Systems Medicine Enhanced targeted delivery of therapeutic agents

Also Published As

Publication number Publication date
BR112021002435A2 (pt) 2021-05-04
US11858982B2 (en) 2024-01-02
CA3107674A1 (en) 2020-02-13
KR20210088523A (ko) 2021-07-14
EP3833404A1 (en) 2021-06-16
CN112770786B (zh) 2023-10-27
CN112770786A (zh) 2021-05-07
JP2024041851A (ja) 2024-03-27
WO2020030827A1 (en) 2020-02-13
MX2021001604A (es) 2021-04-19
US20210238269A1 (en) 2021-08-05
IL280421A (en) 2021-03-25
JP7428696B2 (ja) 2024-02-06
JP2021534121A (ja) 2021-12-09
GB201813137D0 (en) 2018-09-26
IL280421B2 (en) 2024-06-01
AU2019319092A1 (en) 2021-03-18
AU2019319092B2 (en) 2026-04-02
JP7728035B2 (ja) 2025-08-22
IL280421B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
KR102646468B1 (ko) 항-cd47 항체 및 이의 용도
US9951143B2 (en) Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
JP2023099088A (ja) 活性化可能抗ｐｄｌ１抗体、およびその使用方法
JP2023029557A (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
CN111704672B (zh) 抗血浆激肽释放酶抗体
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
US8679497B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP7110369B2 (ja) 抗ｐｄ－１抗体及びその用途
CA2952113A1 (en) Anti-axl antibodies
JP7479281B2 (ja) 抗ｏｘ４０抗体及びその用途
EP2373335B1 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
JP7728035B2 (ja) 抗体による癌治療
CA3107674C (en) Cancer treatment with an antibody
US20250025553A1 (en) Combination therapy for cancer
CN118524851A (zh) 用于癌症的组合疗法
HK40047604B (zh) 抗cd40抗体及其用途
HK1158977B (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof